2023 World Conference on Lung Cancer (Posters)-EP03.06. Development of an Inhibitor for the Treatment of Lung Cancer

Pdf Summary

This presentation discusses the development of a potential inhibitor for the treatment of non-small cell lung cancer (NSCLC). NSCLC is the leading cause of cancer-related deaths globally, and there is a need for new treatment options. The researchers focus on the DNA damage response (DDR), a network of signaling pathways involved in detecting and repairing DNA damage. Failure of the DDR can lead to cancer and tumor growth. The specific protein targeted in this study is COMMD4.<br /><br />The researchers used molecular dynamics, in vitro binding, and mutagenesis techniques to identify the binding pose of COMMD4 with another protein called H2B. These proteins work together to regulate the epigenetic modification of chromatin around damaged DNA sites. Based on the binding pose data, a small molecule inhibitor of COMMD4-H2B was developed.<br /><br />The on-target activity of the inhibitor was assessed using cell viability, DNA repair, and apoptosis assays. The results showed that treatment with the inhibitor led to decreased NSCLC cell viability and the induction of apoptosis in NSCLC cells. These findings suggest that the inhibitor has potential therapeutic effects in aggressive and genetically unstable cancers.<br /><br />Overall, this study provides preliminary evidence for the development of a novel therapeutic targeting the DNA repair pathway in NSCLC. This research has implications for the treatment of the most common type of lung cancer and could potentially offer new options for patients resistant to current therapies.

Asset Subtitle

Amila Suraweera

Meta Tag

Speaker Amila Suraweera

Topic Tumor Biology: Translational Biology - Translational Therapeutics

Keywords

non-small cell lung cancer

NSCLC

inhibitor development

DNA damage response

COMMD4

molecular dynamics

epigenetic modification

small molecule inhibitor

cell viability

apoptosis assays